Robotic surgery gains rapid ground in India, Delhi NCR leads: Experts

India is rapidly scaling up robotic surgery, with procedures rising from 8,912 in 2021 to 44,857 in 2025, while Delhi NCR has emerged as the country’s biggest hub with 39 hospitals using robotic systems. Experts say the next phase could include wider use of telesurgery, remote mentoring and access to specialist care beyond major cities, subject to regulatory and cybersecurity safeguards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EZDxXmd
via IFTTT

Read More

Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims

Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwzvNLP
via IFTTT

Read More

India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO

Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v7L6naV
via IFTTT

Read More

‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s7BoJzj
via IFTTT

Read More

Karnataka flags 52x mark-up on cancer drugs, seeks Centre's intervention

Karnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs and medical devices. The state government has urged the Centre to implement transparency in pricing and regulate trade margins for essential medicines. Mark-ups observed ranged from 10 to over 52 times the actual procurement costs for various items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xKPHXfq
via IFTTT

Read More

Rasayan Labs launches AI-native drug discovery platform at ICT Mumbai

In an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discovery initiatives. This innovative platform merges critical functions, including retrosynthesis and ADMET prediction, to optimize research efficiency. Free access will be granted to researchers at the Institute of Chemical Technology, marking a pivotal collaboration that seeks to dramatically reduce drug development timelines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KhXkoyt
via IFTTT

Read More

From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CkebFWv
via IFTTT

Read More